METHODS	Clinical response through Week 244 was evaluated using the Psoriasis Area and Severity Index ( PASI ) in the Overall Population ( i.e. patients receiving 1 dose of ustekinumab ) , Initial Responders ( i.e. PASI 75 responders [ Weeks 28/40 ] re-randomized at Week 40 to continue every-12-week maintenance ) and Partial Responders ( i.e. < PASI 75 responders adjusted to every-8-week maintenance at Weeks 28 or 40 ) .\